Enjoy complimentary customisation on priority with our Enterprise License!
The vitiligo therapeutics market size is forecast to increase by USD 321.2 million, at a CAGR of 4.25% between 2023 and 2028. In the pharmaceutical industry, the significance of aesthetic medicine continues to grow, with a focus on enhancing patients' appearance and self-confidence. This segment, driven by the increasing popularity of over-the-counter (OTC) and off-label drugs, offers substantial volume growth opportunities. The moderate competitive environment in this sector ensures a balanced demand-supply equation, enabling companies to maintain profitability while catering to consumers' evolving needs. Key players in the aesthetic medicine market invest in research and development to introduce innovative treatments and expand their product portfolios, thereby strengthening their market position. This dynamic industry is expected to continue growth, driven by consumer demand and advancements in medical technology.
Insights from 2018-2023 and future projections for 2024-2028,Get your free sample now
Vitiligo is a dermatology disorder characterized by the appearance of white patches on the human skin due to the loss of melanin pigment. The condition affects the pigment-producing cells, known as melanocytes, leading to the depigmentation of various body parts such as the mouth, hair, palms, neck, eyes, and skin color. The therapeutic market for vitiligo is witnessing significant growth due to the increasing number of clinical trials for effective treatments. Topical treatments, light therapy, and surgical procedures are the primary therapeutic approaches for vitiligo. Topical treatments include corticosteroids, calcineurin inhibitors, and calcipotriene. Light therapy, also known as phototherapy, uses ultraviolet (UV) light to stimulate melanocytes and repigment the affected areas. Surgical procedures, such as skin grafting and melanocyte transplantation, are used for extensive vitiligo cases. Nonsegmental vitiligo, which affects larger areas of the body, is the most common type of vitiligo. Factors contributing to the development of vitiligo include autoimmune physical disorders like Addison's disease and hypothyroidism, mental stress, and skin cancer.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The tropical segment is estimated to witness significant growth during the forecast period. Vitiligo is a condition characterized by the loss of melanin, leading to patches of white skin on various parts of the human body, including the mouth, hair, palms, neck, eyes, and other areas. The vitiligo treatment market encompasses various therapeutic approaches, including topical treatments, light therapy, and surgical procedures. Topical treatments involve the application of medications directly onto the affected skin. Two common topical medications used for vitiligo treatment are Albaquin, a non-prescription cream developed by Puneet Laboratories, and Tacrolimus, an immunosuppressant cream.
Get a glance at the market share of various regions Download the PDF Sample
The topical segment accounted for USD 578.30 million in 2018. Furthermore, light therapy, also known as phototherapy, uses specific wavelengths of light to stimulate melanin production in the skin. Surgical procedures, such as skin grafting and melanocyte transplantation, are used for severe cases of vitiligo. Clinical trials are ongoing to evaluate the safety and efficacy of novel therapies, including stem cell therapy and gene therapy. Dermatologists often prescribe these treatments based on the extent and location of the vitiligo, as well as the patient's overall health and personal preferences. The geriatric population and those with non-segmental vitiligo are at a higher risk for developing this condition. Aesthetic concerns and the desire for even skin tone have also contributed to the growing demand for vitiligo treatments in hospitals, clinics, and aesthetic centers.
For more insights on the market share of various regions Request Free Samplet
North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Vitiligo is a chronic condition characterized by the loss of melanin, leading to depigmentation of patches on the human skin. Topical treatments, such as topical corticosteroids and calcineurin inhibitors, are commonly used to manage the inflammation and swelling associated with vitiligo. Clinical trials are ongoing to evaluate the effectiveness of light therapy and surgical procedures for repigmentation. Hospitals and aesthetic clinics offer various treatments, including grafting techniques and melanocyte transplantation.
Further, novel therapies, such as oral medications like Opzelura, are also being explored to address vitiligo. Dermatology lasers often use pigment-producing cells, such as melanocytes, to assess the severity and progression of the condition. Vitiligo can affect various parts of the body, including the mouth, hair, palms, neck, eyes, and skin color. Risk factors for vitiligo include sunburn, hearing loss, and certain autoimmune diseases. Beauty consciousness and the desire for aesthetic treatments have driven the growth of the vitiligo treatment market. Digital platforms offer access to information and resources for individuals with vitiligo, facilitating better understanding and management of the condition. The geriatric population is particularly susceptible to non-segmental vitiligo, making it a significant focus for medication and surgery development.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing importance of aesthetic appeal is notably driving market growth. Vitiligo, an autoimmune physical disorder characterized by the development of white spots on the skin caused by the loss of melanin pigment, affects approximately 1-2% of the global population. This dermatology disorder, also known as leukoderma or piebald skin, is not life-threatening but can lead to mental stress and social stigma. In emerging economies such as India and China, the growing importance of aesthetic appeal and improving lifestyle are driving the market for vitiligo therapeutics. Melanoma skin examinations are crucial for individuals with vitiligo due to the increased risk of skin cancer. Vitiligo can also affect mucous membranes in some cases, leading to eye problems such as iritis and affecting cochlear melanocytes.
Further, clinical research is ongoing to explore new treatments for vitiligo, including Ruxolitinib, Corticosteroids, and Calcineurin inhibitors. Hospital pharmacies and online providers offer these therapeutics to patients, making them more accessible. Autoimmune diseases, including vitiligo, are linked to conditions such as Addisons' disease and hypothyroidism. While there is no cure for vitiligo, these therapeutics can help manage the symptoms and improve the appearance of affected areas. Thus, such factors are driving the growth of the market during the forecast period.
Growing disposable income in emerging countries is the key trend in the market. Vitiligo, an autoimmune physical disorder characterized by the loss of melanin pigment, leading to white spots on the skin, is a common dermatology disorder. This condition, which can affect any part of the body, including mucous membranes, is prevalent in individuals with autoimmune diseases, such as Addison's disease and hypothyroidism, as well as those experiencing mental stress, iritis, and cochlear melanocytes. While there is no cure for vitiligo, treatments such as corticosteroids and calcineurin inhibitors are commonly used to manage the symptoms. The increasing prevalence of vitiligo, particularly in APAC countries like India and China, has led to a growing demand for therapeutics. North America currently dominates the market for vitiligo therapeutics due to its robust economic growth.
However, the rising awareness and affordability of treatments in APAC countries are expected to drive market growth in these regions. Clinical research is ongoing to explore new treatments, including Ruxolitinib, which has shown promising results in clinical trials. Hospital pharmacies and online providers offer these treatments, making them accessible to a wider population. Melanoma skin examinations are essential for individuals with vitiligo to monitor for potential skin cancer. Overall, the vitiligo therapeutics market is expected to grow significantly in the coming years due to the increasing prevalence of the disease and the availability of effective treatments. Thus, such trends will shape the growth of the market during the forecast period.
Poor patient adherence is the major challenge that affects the growth of the market. Vitiligo, an autoimmune dermatology disorder characterized by the loss of melanin pigment in the skin, leading to white spots or patches, can significantly impact an individual's physical and mental well-being. The condition, which can affect any part of the body, including mucous membranes, is often complicated by various factors that influence adherence to treatment regimens. These factors include the complexity of the treatment process, lack of sufficient information from healthcare providers about the chronic nature and potential side effects of medications, and the cost of branded drugs compared to generic or off-label alternatives. Moreover, some individuals may discontinue treatment after achieving partial remission or due to the presence of comorbidities such as Addison's disease, hypothyroidism, iritis, or mental stress.
Moreover, in clinical research, various therapeutic options, including corticosteroids, calcineurin inhibitors, and Ruxolitinib, are being explored to address the challenges associated with vitiligo treatment. Despite these advancements, access to these treatments may be limited due to insurance coverage or cost concerns, leading to the use of alternative treatments or self-medication. It is essential for healthcare providers to prioritize patient education and support to improve treatment adherence and optimize outcomes for individuals with vitiligo. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Vitiligo is a chronic condition that causes patches of skin to lose pigmentation and turn white. The human skin, which is our largest organ, is responsible for producing melanin, the pigment that gives skin its color. The lack of melanin in vitiligo is due to the damage or destruction of melanocytes, the pigment-producing cells. The Vitiligo treatment market is witnessing significant growth due to the increasing awareness of this condition and the growing demand for effective treatments. Topical treatments, light therapy, exfoliators and scrubs and surgical procedures are the primary approaches used for vitiligo treatment. Hospitals and aesthetic clinics are the major end-users of these treatments. Clinical trials for novel therapies are underway to improve the clinical results of vitiligo treatment. The mouth, hair, palms, neck, eyes, and other areas of the body can be affected by vitiligo. Risk factors for vitiligo include sunburn, hearing loss, and certain autoimmune diseases.
Furthermore, generic medications are also available for vitiligo treatment, and dermatologists are the primary prescribers of these treatments. Opzelura, a topical cream, is a popular treatment for vitiligo. Repigmentation is the ultimate goal of vitiligo treatment, and various methods are being explored to achieve this. The beauty consciousness and aesthetic treatments trend are driving the demand for vitiligo treatments. Digital platforms are also playing a crucial role in increasing awareness and accessibility of these treatments. The geriatric population is another significant end-user of vitiligo treatments due to the higher prevalence of this condition in older adults. Non-segmental vitiligo is the most common form of vitiligo, and surgery and medication are the primary treatment options for this condition.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
144 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.25% |
|
Market growth 2024-2028 |
USD 321.2 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
3.97 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 35% |
|
Key countries |
US, China, Germany, Canada, and UK |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Alkem Laboratories Ltd., AmerisourceBergen Corp., Astellas Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Biocon Ltd., Canixa Life Sciences, Concord Biotech Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., La Pristine Bioceuticals Pvt. Ltd., LEO Pharma AS, Mallinckrodt Plc, Panacea Biotec Ltd., Pfizer Inc., Puneet Laboratories Pvt. Ltd., Sandoz Group AG, Strides Pharma Science Ltd., Teva Pharmaceutical Industries Ltd., Veloxis Pharmaceuticals AS, and Viatris Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.